PADT Found Not to Improve Survival

Primary androgen deprivation  therapy (PADT) is not associated with improved 10-year survival in elderly men with localized prostate cancer when compared with conservative management, according to a study published in The Journal of the American Medical Association (2008;300:173-181).

PADT was associated with a lower 10-year prostate cancer-specific survival.

The study included 19,271 men (median age 77 years), of whom 7,867 received PADT and 11,404 were managed conservatively.

From the September 01, 2008 Issue of Renal and Urology News